Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Recce Pharmaceuticals Ltd. Stock

Price
Target price
€0.15

€0.15

3.380%
0.005
3.380%
-
 
03.07.25 / Stuttgart Stock Exchange WKN: A2ADQM / Name: Recce Pharmaceuticals Ltd. / Stock / ? /
Please give a prediction to see the opinions of the community
Buy
None
Sell
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Recce Pharmaceuticals Ltd. in the next few years
Wizard

Financial data and news for Recce Pharmaceuticals Ltd.

sharewise wants to provide you with the best news and tools for Recce Pharmaceuticals Ltd., so we directly link to the best financial data sources.

Financials

News

Broker

 

News

Recce Pharmaceuticals Enters into DTRA-Backed Cooperative Research & Development Agreement with USAMRIID: https://www.irw-press.at/prcom/images/messages/2025/79390/Recce_280425_PRCOM.001.png
Recce Pharmaceuticals Enters into DTRA-Backed Cooperative Research & Development Agreement with USAMRIID

Highlights:

 

-          Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), the United States’

irwpresse_en 
0 28.04.25
Placement of Entitlement Offer Shortfall
Placement of Entitlement Offer Shortfall

Highlights:

 

-          Entitlement Offer Shortfall of approximately 26.4 million shares placed to existing institutional and sophisticated investors raising A$7.4 million

 

-         

irwpresse_en 
0 03.06.25
China Patent Accepted for RECCE® Anti-Infectives
China Patent Accepted for RECCE® Anti-Infectives

Sydney Australia, 26 May 2025: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) a leading developer of a New Class of Synthetic Anti-Infectives, is pleased to

irwpresse_en 
0 26.05.25
Phase II Clinical Trial Receives Additional Approval for Treating Diabetic Patients with RECCE® 327 Topical Gel
Phase II Clinical Trial Receives Additional Approval for Treating Diabetic Patients with RECCE® 327 Topical Gel

Highlights:

 

-          Human Research Ethics Committee (HREC) approval received to allow up to 20 additional patients access to RECCE® 327 Topical Gel (R327G) treatment under existing

irwpresse_en 
0 22.04.25
Recce Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders
Recce Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to Shareholders

Highlights:

-          A$5.0 million commitment received from Australian-based private investor

-          A$10.8 million Entitlement Offer at the same offer price as the placement

-         

irwpresse_en 
0 10.04.25
Japan Patent Allowance for RECCE® Anti-Infectives
Japan Patent Allowance for RECCE® Anti-Infectives

Sydney Australia, 26 February 2025: Recce Pharmaceuticals Limited (ASX:RCE, FSE:R9Q), (Recce or the Company) the Company developing a New Class of Synthetic Anti-Infectives, is pleased to

irwpresse_en 
0 26.02.25
Positive Phase II Data from Clinical Trial of RECCE® 327 Gel Supports Accelerated Commercialisation Pathway
Positive Phase II Data from Clinical Trial of RECCE® 327 Gel Supports Accelerated Commercialisation Pathway

Highlights:

 

-          Successful Phase II clinical trial assessing efficacy and safety of RECCE® 327 topical gel (R327G) in patients with Acute Bacterial Skin and Skin Structure Infections

irwpresse_en 
0 17.02.25
All Patients Dosed in Phase II Clinical Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections
All Patients Dosed in Phase II Clinical Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure Infections

Highlights:

 

-          All patients (30) dosed in Phase II clinical trial assessing efficacy of RECCE® 327 topical gel (R327G) in Acute Bacterial Skin and Skin Structure Infections

 

-    

irwpresse_en 
0 21.01.25